Is the NIHSS Certification Process Too Lenient?

被引:11
作者
Hills, Nancy K. [1 ]
Josephson, S. Andrew [1 ]
Lyden, Patrick D. [3 ,4 ]
Johnston, S. Claiborne [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, Stroke Sci Grp, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, Stroke Sci Grp, San Francisco, CA 94143 USA
[3] VA Med Ctr, San Diego, CA USA
[4] Univ Calif San Diego, Stroke Ctr, San Diego, CA 92103 USA
关键词
Stroke; NIH Stroke Scale; reliability; Scoring the NIHSS certification test; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-TRIALS; HOSPITAL DISPOSITION; SCALE; RELIABILITY; THROMBOLYSIS; PROUROKINASE; ALTEPLASE;
D O I
10.1159/000209237
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Background and Purpose: The National Institutes of Health Stroke Scale (NIHSS) is a widely used measure of neurological function in clinical trials and patient assessment; inter-rater scoring variability could impact communications and trial power. The manner in which the rater certification test is scored yields multiple correct answers that have changed over time. We examined the range of possible total NIHSS scores from answers given in certification tests by over 7,000 individual raters who were certified. Methods: We analyzed the results of all raters who completed one of two standard multiple-patient videotaped certification examinations between 1998 and 2004. The range for the correct score, calculated using NIHSS 'correct answers', was determined for each patient. The distribution of scores derived from those who passed the certification test then was examined. Results: A total of 6,268 raters scored 5 patients on Test 1; 1,240 scored 6 patients on Test 2. Using a National Stroke Association (NSA) answer key, we found that correct total scores ranged from 2 correct scores to as many as 12 different correct total scores. Among raters who achieved a passing score and were therefore qualified to administer the NIHSS, score distributions were even wider, with 1 certification patient receiving 18 different correct total scores. Conclusions: Allowing multiple acceptable answers for questions on the NIHSS certification test introduces scoring variability. It seems reasonable to assume that the wider the range of acceptable answers in the certification test, the greater the variability in the performance of the test in trials and clinical practice by certified examiners. Greater consistency may be achieved by deriving a set of 'best' answers through expert consensus on all questions where this is possible, then teaching raters how to derive these answers using a required interactive training module. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:426 / 432
页数:7
相关论文
共 29 条
[1]
ENSURING RELIABILITY OF OUTCOME MEASURES IN MULTICENTER CLINICAL-TRIALS OF TREATMENTS FOR ACUTE ISCHEMIC STROKE - THE PROGRAM DEVELOPED FOR THE TRIAL OF ORG-10172 IN ACUTE STROKE TREATMENT (TOAST) [J].
ALBANESE, MA ;
CLARKE, WR ;
ADAMS, HP ;
WOOLSON, RF ;
BENDIXEN, BH ;
DAVIS, PH ;
JACOBY, MR ;
GOMEZ, FJ ;
DYKEN, ME ;
UC, EY ;
WOJCIESZEK, JM ;
KAPPELLE, LJ ;
TANNA, AB ;
MITCHELL, VL ;
GOMEZ, CR ;
MALKOFF, MD ;
TULYAPRONCHOTE, R ;
SAUER, CM ;
RIAZ, G ;
SCHMIDT, JG ;
MALIK, MM ;
BANET, GA ;
KARANJIA, PN ;
MADDEN, KP ;
RUGGLES, KH ;
MICKEL, SF ;
GOTTSCHALK, PG ;
HANSOTIA, PL ;
SORENSON, RW ;
JACOBSON, DM ;
HINER, BC ;
MANCL, K ;
LUKASIK, E ;
BRUNO, A ;
LAKIND, ED ;
JEFFREY, DR ;
MLADINICH, EK ;
IQBAL, J ;
REINERS, M ;
BARRETT, DW ;
SHIBUYA, D ;
WILLIAMS, JK ;
RUSSELL, P ;
KING, MK ;
CHAPIN, JE ;
CARTER, S ;
JEFFRIES, L ;
HIER, DB ;
SHAPIRO, RA ;
BRINT, SU .
STROKE, 1994, 25 (09) :1746-1751
[2]
*AM STROK ASS, 2007, NIH STROK SCAL
[3]
The interventional management of stroke (IMS) II study [J].
Broderick, Joseph P. .
STROKE, 2007, 38 (07) :2127-2135
[4]
MEASUREMENTS OF ACUTE CEREBRAL INFARCTION - A CLINICAL EXAMINATION SCALE [J].
BROTT, T ;
ADAMS, HP ;
OLINGER, CP ;
MARLER, JR ;
BARSAN, WG ;
BILLER, J ;
SPILKER, J ;
HOLLERAN, R ;
EBERLE, R ;
HERTZBERG, V ;
RORICK, M ;
MOOMAW, CJ ;
WALKER, M .
STROKE, 1989, 20 (07) :864-870
[5]
A randomized efficacy trial of citicoline in patients with acute ischemic stroke [J].
Clark, WM ;
Williams, BJ ;
Selzer, KA ;
Zweifler, RM ;
Sabounjian, LA ;
Gammans, RE .
STROKE, 1999, 30 (12) :2592-2597
[6]
Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[7]
Selfotel in acute ischemic stroke - Possible neurotoxic effects of an NMDA antagonist [J].
Davis, SM ;
Lees, KR ;
Albers, GW ;
Diener, HC ;
Markabi, S ;
Karlsson, G ;
Norris, J .
STROKE, 2000, 31 (02) :347-354
[8]
PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke [J].
del Zoppo, GJ ;
Higashida, RT ;
Furlan, AJ ;
Pessin, MS ;
Rowley, HA ;
Gent, M .
STROKE, 1998, 29 (01) :4-11
[9]
FEEDBACK IN CLINICAL MEDICAL-EDUCATION [J].
ENDE, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 250 (06) :777-781
[10]
Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011